Aurobindo (incl. Aurolife) now has a total of 193 ANDA approvals (165 Final approvals and 28 Tentative approvals) from USFDA.
Aurobindo Pharma Limited announced that US Food & Drug Administration (USFDA) has granted the tentative approval for Lacosamide Tablets 50mg, 100mg, 150mg and 200mg (ANDA 204994).
Lacosamide Tablets are the generic equivalent of USB Inc’s Vimpat® Tablets and used in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older with a market size of approximately US$ 593 Million for the twelve months ending January 2015 according to IMS.
This ANDA contains a Paragraph IV certification and is currently under litigation in the United States District Court for the District of Delaware [UCB Inc, UCB Pharma GMBH Research Corporation Technologies Inc. and Harris FRC Corporation v. Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc, Civil Action No. 1:13-cv-01210-UNA].
Aurobindo (incl. Aurolife) now has a total of 193 ANDA approvals (165 Final approvals and 28 Tentative approvals) from USFDA.
At 2:28 PM, the stock were trading higher 2.3% at Rs.1,272. The stock has hit a high of Rs. 1,279 and a low of Rs.1,250.
Total traded quantity on the counter stood at over 1.05 lk shares on BSE.
Meanwhile, the benchmark BSE Sensex is trading at 28,707 up 85 points
Lacosamide Tablets are the generic equivalent of USB Inc’s Vimpat® Tablets and used in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older with a market size of approximately US$ 593 Million for the twelve months ending January 2015 according to IMS.
This ANDA contains a Paragraph IV certification and is currently under litigation in the United States District Court for the District of Delaware [UCB Inc, UCB Pharma GMBH Research Corporation Technologies Inc. and Harris FRC Corporation v. Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc, Civil Action No. 1:13-cv-01210-UNA].
Aurobindo (incl. Aurolife) now has a total of 193 ANDA approvals (165 Final approvals and 28 Tentative approvals) from USFDA.
At 2:28 PM, the stock were trading higher 2.3% at Rs.1,272. The stock has hit a high of Rs. 1,279 and a low of Rs.1,250.
Total traded quantity on the counter stood at over 1.05 lk shares on BSE.
Meanwhile, the benchmark BSE Sensex is trading at 28,707 up 85 points
No comments:
Post a Comment